Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$0.00
$4.35
$11.97
$1.01B4.52528,025 shs1.43 million shs
Endo International plc stock logo
ENDP
Endo International
$0.45
$0.28
$7.07
$141K1.1528.19 million shs9,967 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$30.56
-3.1%
$24.79
$16.16
$31.88
$1.24B0.75221,889 shs295,791 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.54
-5.7%
$6.92
$2.21
$19.71
$596.18M0.451.54 million shs882,041 shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$33.51
-1.3%
$32.26
$27.05
$40.28
$1.88B0.7488,777 shs676,462 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00%0.00%0.00%0.00%0.00%
Endo International plc stock logo
ENDP
Endo International
0.00%0.00%0.00%0.00%0.00%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+2.40%+5.48%+31.80%+87.63%+80.43%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-1.31%+4.62%-14.85%+89.94%-22.23%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
+2.54%+7.98%+6.03%+7.95%+18.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
0.2305 of 5 stars
0.00.00.03.50.01.70.0
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
4.0203 of 5 stars
0.94.02.51.13.23.32.5
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
4.2032 of 5 stars
4.54.00.00.01.65.00.6
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
1.6594 of 5 stars
1.21.00.04.13.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
0.00
N/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
0.00
N/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-20.16% Downside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.50104.92% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.33
Hold$36.007.43% Upside

Current Analyst Ratings Breakdown

Latest PAHC, PHAT, ENDP, SUPN, and CNTTF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
5/8/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $12.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $20.00
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
$15.96M0.00N/AN/AN/ANaN
Endo International plc stock logo
ENDP
Endo International
$2.99B0.00N/A0.06($13.60) per share0.00
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.22$2.10 per share14.57$6.34 per share4.82
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$55.25M10.79N/AN/A($3.71) per share-2.30
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$668.00M2.81$4.22 per share7.94$18.76 per share1.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A$0.07137.180.00N/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
-$613.24M-$11.07N/A0.00N/A-93.31%-34.25%6.72%N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7839.1814.550.522.68%30.51%6.89%8/27/2025 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$73.86M$1.1130.1923.27N/A9.27%12.23%9.17%8/5/2025 (Estimated)

Latest PAHC, PHAT, ENDP, SUPN, and CNTTF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$0.47N/AN/AN/A$154.06 millionN/A
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.57%N/A61.54%N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest PAHC, PHAT, ENDP, SUPN, and CNTTF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/AN/AN/A
Endo International plc stock logo
ENDP
Endo International
N/A
1.86
1.62
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
3.58
3.54
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
2.44
2.26
CompanyEmployeesShares OutstandingFree FloatOptionable
CannTrust Holdings Inc stock logo
CNTTF
CannTrust
N/A105.61 millionN/ANot Optionable
Endo International plc stock logo
ENDP
Endo International
3,103235.14 million232.32 millionNo Data
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.81 million52.99 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
58055.99 million51.06 millionOptionable

Recent News About These Companies

Supernus Pharmaceuticals, Inc. (SUPN) - Yahoo Finance
Sage Sacks Entire Staff After Supernus Buyout

New MarketBeat Followers Over Time

Media Sentiment Over Time

CannTrust stock logo

CannTrust OTCMKTS:CNTTF

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

Endo International stock logo

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$30.56 -0.98 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$30.56 0.00 (-0.02%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$8.54 -0.52 (-5.74%)
Closing price 04:00 PM Eastern
Extended Trading
$8.60 +0.06 (+0.69%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$33.51 -0.45 (-1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$33.48 -0.03 (-0.09%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.